Managing thromboembolic risk with menopausal hormone therapy and hormonal contraception in the COVID-19 pandemic
Guía de recomendaciones de la Sociedad Española de Trombosis y Hemostasia (SETH), la Asociación Española para el Estudio de la Menopausia (AEEM) y la Sociedad Española de Ginecología y Obstetricia (SEGO).
COVID-19 is associated with a systemic inflammatory response with activation of coagulation in symptomatic patients. The possibility of coagulopathies in peri- and postmenopausal women taking estrogen therapies makes it necessary to consider antithrombotic strategies, such as the use of low molecular weight heparins (LMWH) at specific prophylactic or treatment doses for each individual case, depending on the risk factors that each woman presents.
For such reasons, a panel of experts from various Spanish scientific societies has met to develop usage recommendations for managing menopausal women taking menopausal hormone therapy (MHT) or combined hormonal contraception (CHC) during the COVID-19 pandemic.